Tailored therapeutic strategies have significantly enhanced patient outcomes across numerous cases of non-Hodgkin B-cell lymphomas—hematological malignancies originating from immune cells known as B cells. However, this advancement has not been mirrored for individuals afflicted with rarer lymphoma subtypes that stem from immune cells identified as T cells.
Peripheral T-cell lymphomas encompass a heterogeneous group of blood cancers characterized by distinct biological underpinnings, with survival rates exhibiting considerable variability. Dr. Jia Ruan, a distinguished lymphoma specialist and professor of clinical medicine at Weill Cornell Medicine, alongside her research associates, is actively engaged in transforming this landscape.
Our prior assumption was that a universal treatment paradigm could be applied to all non-Hodgkin lymphomas. We are now recognizing the imperative to develop individualized diagnostic, therapeutic, and prognostic frameworks specifically for T-cell lymphomas.
Dr. Jia Ruan, a member of the Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine and a hematologist/oncologist at NewYork-Presbyterian/Weill Cornell Medical Center
In her co-leadership of the T-cell lymphoma Working Group within the multi-institutional Lymphoma Epidemiology of Outcomes (LEO) Consortium, Dr. Ruan, in collaboration with Dr. Andrew Feldman from the Mayo Clinic, has contributed to uncovering novel insights into peripheral T-cell lymphoma that hold the potential for personalized care modalities.
“The landmark real-world data study we recently disseminated provided crucial understanding of the expected trajectory for the majority of T-cell lymphoma patients undergoing conventional chemotherapy-centric management,” stated Dr. Ruan. “This establishes a vital benchmark, enabling us to pinpoint areas of unmet need and strategically define our clinical development priorities.”
We engaged in a discussion with Dr. Ruan to gain deeper insights into her research endeavors and their anticipated impact on lymphoma patient care.
How has Weill Cornell Medicine collaborated with other institutions to advance lymphoma treatment?
Weill Cornell Medicine has been an integral member of the LEO consortium, an amalgamation of eight premier U.S. medical centers possessing specialized expertise in lymphoma management, since its inception in 2015 with funding from the National Cancer Institute. The consortium’s overarching objective is to compile and sustain a substantial, diverse, and prospective patient cohort with non-Hodgkin lymphoma to identify novel clinical, epidemiological, genetic, tumor-related, and treatment factors that influence patient outcomes.
Specifically, how is the LEO consortium contributing to addressing the challenges associated with peripheral T-cell lymphomas?
It serves as an ideal resource for managing a rare disease like peripheral T-cell lymphoma. By pooling multicenter, multidisciplinary resources, it facilitates the creation of a sufficiently large database, allowing for in-depth investigation into the specifics of each of the over 30 disease subtypes. In smaller datasets, the analysis of subtypes can rapidly fragment and diminish the sample size, thus hindering the ability to explore questions concerning subtype-specific disease factors or treatment patterns. We are able to conduct empirical outcome analyses across various disease subtypes and identify where needs are most pressing, whether in understanding the underlying biology, developing more efficacious treatments, or addressing access-to-care disparities.
What significant findings have emerged from your research to date?
By concentrating on over 700 peripheral T-cell lymphoma patients within the LEO cohort, we have been able to chart the evolution of treatment approaches concerning initial therapy over the preceding two decades. Our findings indicate that, broadly speaking, the foundational treatment regimen remains remarkably consistent, primarily involving a chemotherapy regimen developed for B-cell non-Hodgkin’s lymphoma patients, known as CHOP (comprising cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and prednisone). Concurrently, our comprehension of the biology and classification of peripheral T-cell lymphoma has expanded, and a growing array of novel targeted agents demonstrating clinical activity in T-cell lymphoma has become available, paving the way for biology-driven therapeutic advancements.
In what ways do you envision care for these patient demographics being enhanced?
Our aspiration is to build upon the existing CHOP regimen and develop initial therapeutic interventions tailored to specific subtypes. More critically, we aim to introduce innovative agents targeting particular biological pathways. The LEO cohort data empowers us to monitor the real-world impact of targeted agents, such as the anti-CD30 antibody-drug conjugate brentuximab vedotin (BV) and other agents employed in clinical trials and clinical practice. We are beginning to observe a trend of improvement with the novel agent BV in the anaplastic large cell lymphoma subtype; however, the sample size of patients who have received newer treatments within our current analysis remains insufficient. We anticipate that further analyses, as the LEO cohort expands and matures, will corroborate these emergent trends. For the majority of other subtypes, our objective is to identify therapies that can be implemented based on biological biomarkers to improve patient outcomes.
What are the forthcoming objectives for the LEO consortium’s investigations into peripheral T-cell lymphoma?
Our aim is to investigate whether underlying biological differences contribute to outcome disparities. The subsequent phase involves undertaking a contemporary multi-omic characterization of the tumor biospecimens, encompassing genomics, transcriptomics, and interactive signals between the tumor and its microenvironment. This comprehensive approach will yield a more profound understanding of potential targets for novel therapeutics. The forthcoming data will inform our patient treatment strategies and the sequence in which new agents are administered, guided by their mutation profiles in conjunction with their clinical prognostic scores. Furthermore, it may facilitate the development of precision prognostic models for patient management.
What are the subsequent stages for your research initiatives?
We will persist in our involvement with LEO and the recruitment of patients for the study. In close collaboration with the Mayo Clinic, we are overseeing and directing the LEO T-cell lymphoma multi-omics analysis utilizing the preserved specimens. Additionally, we will be partnering with our colleagues to develop and evaluate new therapeutics through clinical trials. Our commitment is to expedite the introduction of novel therapies for our patient populations.
What unique contributions do you believe your team at Weill Cornell Medicine brings to patients as they navigate this evolving landscape of peripheral T-cell lymphoma care?
Weill Cornell Medicine is exceptionally positioned to embrace this cutting-edge, collaborative, and multidisciplinary methodology. We maintain ongoing partnerships with our esteemed hemopathology team, under the leadership of Dr. Giorgio Inghirami, and with translational scientists at the Englander Institute for Precision Medicine, directed by Dr. Olivier Elemento. These groups possess a well-established track record in developing molecular therapeutic and prognostic models for a variety of lymphomas. Our current endeavor is to leverage this expertise for peripheral T-cell lymphoma.
Our clinical research cadre has been instrumental in introducing numerous novel therapies to our patients within clinical trial settings, often well in advance of their widespread adoption as standard of care. We recently published the findings of a phase 2 trial evaluating a chemotherapy-free treatment regimen for individuals newly diagnosed with mantle cell lymphoma, a rare and aggressive subtype of non-Hodgkin B-cell lymphoma. The encouraging outcomes support the utilization of this new combination therapy as a frontline treatment for the condition. We aspire to continue delivering this caliber of pioneering care by bringing improved therapeutic options to our patients with peripheral T-cell lymphoma.
